November 29, 2022
Loading...
You are here:  Home  >  Banking & Finance  >  Current Article

Atara reports Q1 loss as it pursues EU and FDA approvals

IN THIS ARTICLE

Atara Biotherapeutics continues to see net losses mount as it awaits news from the U.S. Food and Drug Administration, but the sale of its Thousand Oaks manufacturing facility for $100 million will help fund operations for the next two years. Atara, a South San Francisco-based immunotherapy company with its major operations in Thousand Oaks, reported…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.